Can GLP-1 receptor agonists extend healthspan and longevity beyond their established role in obesity treatment?
Can GLP-1 receptor agonists extend healthspan and longevity beyond their established role in obesity treatment?
Based on the provided sources, what specific plasma and CSF biomarkers are being tracked in the evoke and evoke+ phase 3 trials to measure neuroinflammation and neurodegeneration outcomes?
What are the long-term effects of GLP-1 receptor agonists on muscle mass, bone health, and physical function, particularly in older adults?
Want to take this research further?
Sign up free and the thread will land in your workspace so you can refine the question, ask follow-ups, or branch into related searches.